PDF herunterladen
CC BY 4.0 · Indian J Med Paediatr Oncol 2024; 45(01): 080-082
DOI: 10.1055/s-0043-1770926
Case Report with Review of Literature

A Case Report and Literature Review of Primary Central Nervous System Lymphoma in a Patient with Crigler–Najjar Syndrome: How We Managed

Udip Maheshwari
1   Medical Oncology Department, Mumbai Oncocare Centre, Mumbai, Maharashtra, India
,
Disha Morzaria 
1   Medical Oncology Department, Mumbai Oncocare Centre, Mumbai, Maharashtra, India
,
Seema Jagiasi
1   Medical Oncology Department, Mumbai Oncocare Centre, Mumbai, Maharashtra, India
,
Vashishth Maniar
1   Medical Oncology Department, Mumbai Oncocare Centre, Mumbai, Maharashtra, India
,
Ashish Joshi
1   Medical Oncology Department, Mumbai Oncocare Centre, Mumbai, Maharashtra, India
,
Sameer Soneji
2   Infinity Scan Centre, Mumbai, Maharashtra, India
› Institutsangaben Funding None declared.
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare form of CNS tumor that can be managed with curative intent using high-dose chemotherapeutic drugs. High-dose methotrexate is an essential drug for the management of PCNSL. We present a case of a 26-year-old man with a known comorbidity of Crigler–Najjar syndrome type II and a baseline bilirubin of 13.5 mg/dL, presented with somnolence and ataxia. In view of hyperbilirubinemia, the optimal treatment for CNS lymphoma, the De Angelis protocol, was modified for this patient. The patient tolerated the chemotherapy well with manageable fluctuations in bilirubin levels, followed by consolidation with whole-brain radiotherapy. He remains asymptomatic 6 months after the onset of the symptoms with the disease in complete remission. We highlight here this unusual case of PCNSL where high-dose methotrexate was used with close observation of liver function in view of hyperbilirubinemia in a known case of Crigler–Najjar syndrome.

Keywords

Crigler–Najjar syndrome - DeAngelis protocol - hyperbilirubinemia - primary CNS lymphoma

Patient's Consent

Informed consent was obtained from all individual participants included in the study.




Publikationsverlauf

Artikel online veröffentlicht:
22. September 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Zeng X, Lu X, Li X, Peng L, Chen L. A case report of primary central nervous system lymphoma. J Int Med Res 2020; 48 (07) 300060520937839
    CrossrefPubMedSuche in Google Scholar
  • 2 Green K, Hogg JP. Central Nervous System Lymphoma. StatPearls Publishing; 2022. Accessed December 5, 2022 at: https://www.ncbi.nlm.nih.gov/books/NBK545145/
  • 3 Kumari S. Methotrexate induced hepatotoxicity and its management. Int J Sci Res 2013; 5 (09) 1477-1481
    Suche in Google Scholar
  • 4 Sasani M, Bayhan M, Sasani H. et al. Primary central nervous system lymphoma presenting as a pure third ventricular lesion: a case report. J Med Case Reports 2011; 5 (01) 213
    CrossrefPubMedSuche in Google Scholar
  • 5 Song KW, Issa S, Batchelor T. Primary central nervous system lymphoma: epidemiology and clinical presentation. Ann Lymphoma 2021; 5: 16
    CrossrefSuche in Google Scholar
  • 6 Rahman MA, Islam MSU, Tasnim N. Crigler Najjar syndrome type 2: a case of unexplained jaundice in an adult. Faridpur Med Coll J 2020; 15 (01) 43-45
    CrossrefSuche in Google Scholar
  • 7 Kumar P, Sasmal G, Gupta S, Saxena R, Kohli S. Crigler Najjar syndrome type 2 (CNS type 2): an unwonted cause of jaundice in adults. J Clin Diagn Res 2017; 11 (07) OD05-OD06
    PubMedSuche in Google Scholar
  • 8 Barker JA, Marini BL, Bixby D, Perissinotti AJ. Successful use of high-dose cytarabine in a patient with acute myeloid leukemia and severe hepatic dysfunction. J Oncol Pharm Pract 2016; 22 (06) 811-815
    CrossrefPubMedSuche in Google Scholar